X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ALKEM LABORATORIES Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

ALKEM LABORATORIES  (ALKE)


Here is the latest financial fact sheet of . For more details, see the quarterly results and share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
alkem laboratories - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 2,182.8       No. of shares m 119.57
    Mkt Cap Rs m 260,981       % ch % 0.6
    Vol '000 6.4       % ch week % 11.8
    P/E X         % ch 1-mth % 5.3
    P/CF X 33.2       % ch 12-mth % 60.9
    EPS (TTM) Rs 0.0       52 week H/L Rs 2,217.0/1,175.0
(As on Mar 23, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High RsNA1,589 
Low RsNA1,232 
Sales per share (Unadj.) Rs313.1417.5 
Earnings per share (Unadj.) Rs32.756.3 
Diluted earnings per shareRs32.856.3 
Cash flow per share (Unadj.) Rs38.764.7 
Dividends per share (Unadj.) Rs012.70 
Adj. dividends per shareRs0.0012.70 
Dividend yield (eoy) %NM0.9 
Book value per share (Unadj.) Rs250.8292.9 
Adj. book value per shareRs250.8292.9 
Shares outstanding (eoy) m119.57119.57 
Bonus/Rights/Conversions  -- 
Price / Sales ratio x03.4 
Avg P/E ratio x025.1 
P/CF ratio (eoy) x021.8 
Price / Book Value ratio x04.8 
Dividend payout %022.6 
Avg Mkt Cap Rs m0168,653 
No. of employees `000NANA 
Total wages/salary Rs m6,4599,171 
Avg. sales/employee Rs ThNMNM 
Avg. wages/employee Rs ThNMNM 
Avg. net profit/employee Rs ThNMNM 
  INCOME DATA
Net Sales Rs m37,43449,915 
Other income Rs m1,8101,645 
Total revenues Rs m39,24451,561 
Gross profit Rs m4,2188,482 
Depreciation Rs m7091,006 
Interest Rs m811671 
Profit before tax Rs m4,5088,451 
Minority Interest Rs m0-114 
Prior Period Items Rs m00 
Extraordinary Inc (Exp) Rs m00 
Tax Rs m5921,606 
Profit after tax Rs m3,9166,731 
Gross profit margin %11.317.0 
Effective tax rate %13.119.0 
Net profit margin %10.513.5 
  BALANCE SHEET DATA
Current assets Rs m23,38127,062 
Current liabilities Rs m20,06015,324 
Net working cap to sales %8.923.5 
Current ratio x1.21.8 
Inventory Days Days7667 
Debtors Days Days5141 
Net fixed assets Rs m11,42912,610 
Share capital Rs m239239 
"Free" reserves Rs m29,58834,490 
Net worth Rs m29,99135,027 
Long term debt Rs m3341,212 
Total assets Rs m52,95854,387 
Interest coverage x6.613.6 
Debt to equity ratio x00 
Sales to assets ratio x0.70.9 
Return on assets %8.913.6 
Return on equity %13.119.2 
Return on capital %17.524.9 
Exports to sales %9.212.9 
Imports to sales %3.93.1 
Exports (fob) Rs m3,4446,461 
Imports (cif) Rs m1,4561,540 
Fx inflow Rs m3,5166,563 
Fx outflow Rs m2,5903,012 
Net fx Rs m9263,552 
  CASH FLOW
From Operations Rs m 3,255 7,259 
From Investments Rs m -2,370 1,864 
From Financial Activity Rs m -518 -9,273 
Net Cashflow Rs m 367 -150 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for alkem laboratories

 Share Holding
Indian Promoters : 66.9%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 33.1%
FIIs : 0.0%
ADR/GDR : 0.0%
Free float : 0.0%
Shareholders : 68,381
Pledged promoter(s) holding : 0.0%
 Company Information
Top
    REGD OFF: Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai-13
    E-MAIL: investors@alkem.com     WEB: www.alkemlabs.com
    TELEPHONE: 02239829999     FAX:
    SECTOR: PHARMACEUTICALS     GROUP:
    TR AGENT: Link Intime India Pvt Ltd
CHM: Mr. Samprada Singh COMP SEC: Mr. Manish Narang YEAR OF INC: 1973 BSE CODE: 539523 FV (Rs): 2 DIV YIELD (%): 0.6

More pharmaceuticals Company Fact Sheets:   AJANTA PHARMAVENUS REMEDIESPLETHICO PHARMAAUROBINDO PHARMATTK HEALTHCARE


Today's Market

Sensex Closes Firm; NTPC Surges 2.3%(Closing)

Indian share markets continued to trade higher owing to firm global cues with energy stocks leading the gains, while financial stocks and auto stocks bounced back.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

Why You Should Try SCOREFASTTM Right Now(Daily Profit Hunter)

Mar 10, 2017

Asad Dossani discusses why SCOREFASTM will be a successful trading strategy

4 Things To Watch Out For After Modi's Landslide Win In UP Polls(Outside View)

Mar 15, 2017

PersonalFN explains why you need to wary while investing in equities despite Modi's UP win.

More

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - MYLAN COMPARISON

Compare Company With Charts

COMPARE ALKEM LABORATORIES WITH

MARKET STATS